Results 11 to 20 of about 1,413,284 (292)

Pediatric pulmonary hypertension. [PDF]

Cardiovasc Diagn Ther, 2021
Apitz C, Lammers AE.
europepmc   +6 more sources

Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors [PDF]

Pulmonary Circulation
Pulmonary hypertension (PH) is a severe complication observed in pediatric patients after hematopoietic cell transplantation or chemotherapy. A review of records at Hokkaido University Hospital (2014–2024) identified four cases of PH, each with different
Ayako Chida‐Nagai, Yukayo Terashita, Shinsuke Hirabayashi, Hirokuni Yamazawa, Yuko Cho, Atsushi Manabe   +5 more
doaj   +2 more sources

Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In pulmonary arterial hypertension, it is recommended to base therapeutic decisions on risk stratification. This systematic review aims to report the prognostic value of serial risk stratification in adult and pediatric pulmonary arterial ...
Chantal Lokhorst, Sjoukje van der Werf, Rolf M. F. Berger, Johannes M. Douwes   +3 more
doaj   +3 more sources

Pediatric Pulmonary Hypertension: A Systematic Approach. [PDF]

JACC Case Rep
Corson A, Philip R, Tailor N, Chakraborty A, Littleford K, McCormick G, Walsh A.   +6 more
europepmc   +2 more sources

Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities

Frontiers in Cardiovascular Medicine, 2022
Cor triatriatum sinister is a rare congenital anomaly characterized by the left-sided triatrial form of the heart. Diverse theories have been proposed regarding its formation, and the failure of incorporation of the common pulmonary vein into the left ...
I-Hsin Tai, I-Hsin Tai, I-Hsin Tai, Tsung-Cheng Shyu, Tsung-Cheng Shyu, Tsung-Cheng Shyu, Kai-Sheng Hsieh, Kai-Sheng Hsieh, Kai-Sheng Hsieh, Ke-Wei Chen, Ke-Wei Chen, Wan-Jane Tsai, Kuo-Yang Wang, Kuo-Yang Wang, Kuo-Yang Wang   +14 more
doaj   +1 more source

Application of [18F]FLT‐PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers [PDF]

, 2021
Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Onno A. Spruijt, Jansen, Samara MA, Anton V. Noordegraaf, Botros, Liza, Liza Botros, Ashek, Ali, de Man, Frances S, Bogaard, Harm J., Marc C. Huisman, Tramper, Jelco, Spruijt, Onno A., Harms, Hans, Jelco Tramper, Samara M.A. Jansen, Jansen, Samara M. A., Hans Harms, Anton Vonk Noordegraaf, Harm J. Bogaard, de Man, Frances S., Bogaard, Harm J, Zhao, Lan, Aman, Jurjan, Ali Ashek, Frances S. de Man, Frances S. deMan, Noordegraaf, Anton V., Spruijt, Onno A, Huisman, Marc C., Huisman, Marc C, Lan Zhao, Noordegraaf, Anton, Jurjan Aman   +31 more
core   +1 more source

A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients

Frontiers in Pediatrics, 2023
IntroductionThe clinical deterioration commonly experienced by pediatric patients with pulmonary arterial hypertension (PAH) has motivated a shift in the treatment of pulmonary hypertension (PH) through innovations in surgical salvage interventions.
David Edward Youssef, Konstantin Averin, Konstantin Averin, Susan Richards, Catherine Sheppard, Cameron Seaman, Matthew Pietrosanu, Angela Bates, Angela Bates   +8 more
doaj   +1 more source

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

Frontiers in Pediatrics, 2023
IntroductionPhosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH).
David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates, Angela Bates   +9 more
doaj   +1 more source

The diagnostic and prognostic role of amino-terminal pro-brain type natriuretic peptides in pediatric cardiac diseases and pulmonary hypertension

Heart Vessels and Transplantation, 2021
Objective: Several studies showed that N-terminal pro-brain type natriuretic peptide (NT-pro-BNP) as the reliable marker both in diagnostic and prognostic workup of pediatric patients with congenital heart disease complicated by pulmonary hypertension ...
Kayirnisa T. Tilemanbetova, Taalaibek Z. Kudaiberdiev, Jalil Sheishenov, Damirbek A. Abibillaev   +3 more
doaj   +1 more source

Tetrahydrobiopterin analogues with NO-dependent pulmonary vasodilator properties [PDF]

, 2011
Reduced NO levels due to the deficiency of tetrahydrobiopterin (BH4) contribute to impaired vasodilation in pulmonary hypertension Due to the chemically unstable nature of BH4 it was hypothesised that oxidatively stable analogues of BR, would be able to ...
Roger M. Wadsworth, Gibson, Colin, Milliken, P. H., Wadsworth, R. M., Philip H. Milliken, Kunuthur, S. P., Suma P. Kunuthur, Colin J. Suckling, Suckling, C. J., Colin L. Gibson   +9 more
core   +4 more sources